Physiological myocardial hypertrophy: how and why?

被引:75
作者
Catalucci, Daniele [1 ,2 ]
Latronico, Michael V. G. [2 ]
Ellingsen, Oyvind [3 ,4 ]
Condorelli, Gianluigi [1 ,2 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Cardiol, La Jolla, CA 92093 USA
[2] MultiMed Hosp, IRCCS, I-20100 Milan, Italy
[3] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway
[4] St Olavs Hosp, Dept Cardiol, Trondheim, Norway
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2008年 / 13卷
关键词
heart; hypertrophy; IGF1; Akt; review;
D O I
10.2741/2681
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardiac hypertrophy is defined by augmentation of ventricular mass as a result of increased cardiomyocyte size, and is the adaptive response of the heart to enhanced hemodynamic loads due to either physiological stimuli (post-natal developmental growth, training, and pregnancy) or pathological states (such as hypertension, valvular insufficiency, etc). The mechanisms leading to hypertrophy during pathological and physiological states are distinct but, in general, evidence indicates that hypertrophy results from the interaction of mechanical forces and neurohormonal factors. Hemodynamic overload creates a mechanical burden on the heart and results in stretch of the myocyte and induction of gene expression of cardiac growth factors. Insulin-like growth factor 1 (IGF1) has recently been shown to be the most important cardiac growth factor involved in physiological hypertrophy. In this review, IGF1 and the pathways it triggers will be discussed.
引用
收藏
页码:312 / 324
页数:13
相关论文
共 108 条
  • [1] Phosphoinositide 3-kinase γ:: kinase-dependent and -independent activities in cardiovascular function and disease
    Alloatti, G
    Montrucchio, G
    Lembo, G
    Hirsch, E
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 : 383 - 386
  • [2] The catalytic subunit of protein phosphatase 2A associates with the translation termination factor eRF1
    Andjelkovic, N
    Zolnierowicz, S
    VanHoof, C
    Goris, J
    Hemmings, BA
    [J]. EMBO JOURNAL, 1996, 15 (24) : 7156 - 7167
  • [3] Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo
    Antos, CL
    McKinsey, TA
    Frey, N
    Kutschke, W
    McAnally, J
    Shelton, JM
    Richardson, JA
    Hill, JA
    Olson, EN
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) : 907 - 912
  • [4] THE EARLIEST ACHEULEAN FROM KONSO-GARDULA
    ASFAW, B
    BEYENE, Y
    SUWA, G
    WALTER, RC
    WHITE, TD
    WOLDEGABRIEL, G
    YEMANE, T
    [J]. NATURE, 1992, 360 (6406) : 732 - 735
  • [5] Ayoub Chakib M, 2002, Curr Opin Anaesthesiol, V15, P285, DOI 10.1097/00001503-200206000-00002
  • [6] BIOLOGICAL SIGNIFICANCE OF CARDIAC HYPERTROPHY
    BADEER, HS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1964, 14 (02) : 133 - +
  • [7] Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression
    Belke, DD
    Betuing, S
    Tuttle, MJ
    Graveleau, C
    Young, ME
    Pham, M
    Zhang, DF
    Cooksey, RC
    McClain, DA
    Litwin, SE
    Taegtmeyer, H
    Severson, D
    Kahn, CR
    Abel, ED
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (05) : 629 - 639
  • [8] Why is left ventricular hypertrophy so predictive of morbidity and mortality?
    Benjamin, EJ
    Levy, D
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1999, 317 (03) : 168 - 175
  • [9] Brodde OE, 1999, PHARMACOL REV, V51, P651
  • [10] BETA-ADRENOCEPTORS IN CARDIAC DISEASE
    BRODDE, OE
    [J]. PHARMACOLOGY & THERAPEUTICS, 1993, 60 (03) : 405 - 430